Table 2:

Factors Associated with RA Biologic or JAKi Treatment Switch (n=60,596 patients analyzed)

	Adjusted* Odds Ratio (95% CI)
MBDA Score  Low (referent)  Moderate (30–44)  High (>44)	1.0 1.51 (1.35 – 1.69) 2.62 (2.26 – 3.05)
Age (5 year increments)	0.91 (0.89 – 0.92)
Male sex (female referent)	0.85 (0.79 – 0.91)
Low income**	1.16 (1.07 – 1.25)
Race (Caucasian referent)  Black  Other	0.76 (0.69 – 0.84) 0.93 (0.86 – 1.01)
Fibromyalgia	1.13 (1.05 – 1.21)
Charlson comorbidity index  0  1  2  3+	1.0 (referent) 1.24 (1.10–1.40) 1.25 (1.10–1.42) 1.38 (1.12–1.47)
Recent hospitalization	1.18 (1.10–1.28)
RA medications  TNFi biologic  Non-TNFi biologic  MTX  HCQ/SSZ/LEF  Glucocorticoid	0.60 (0.52 – 0.68) 0.57 (0.47 – 0.68) 1.09 (1.02 – 1.16) 1.01 (0.95 – 1.08) 1.40 (1.33–1.48)

JAKi = janus kinase inhibitor

^*also adjusted for diabetes, chronic pulmonary disease, obesity, and being disabled, none of which were significant, and also for physician clustering (OR = 1.19, 95% CI 1.06 – 1.34)

^**reflected by state buy-in for Medicare premiums